Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04332991 · ClinicalTrials.gov registry record · Phase 3
Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease
A Phase 3 study of Coronavirus and SARS-CoV Infection, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 479
- Enrollment target
- 20
- Study locations
NCT04332991 is a Phase 3 study of Coronavirus and SARS-CoV Infection that has completed, run by Massachusetts General Hospital. The registered enrollment target is 479 participants, below the 1,381-participant average among 20 other Coronavirus trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT04332991, a Phase 3 study of Coronavirus and SARS-CoV Infection, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 479 participants
- Enrollment target
- 20
- Study locations
Study Summary
ORCHID is a multicenter, blinded, placebo-controlled, randomized clinical trial evaluating hydroxychloroquine for the treatment of adults hospitalized with COVID-19. Patients, treating clinicians, and study personnel will all be blinded to study group assignment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Hydroxychloroquine
Study Locations (20)
California
- UCSF Fresno - Fresno
- Ronald Reagan UCLA Medical Center - Los Angeles
- UC Davis Medical Center - Sacramento
- UCSF Medical Center - San Francisco
- Stanford University - Stanford
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Brigham and Women's Hospital - Boston
- Baystate Medical Center - Springfield
- St. Vincent's Hospital - Worcester
Colorado
- Medical Center of Aurora - Aurora
- University of Colorado Hospital - Aurora
- Denver Health Medical Center - Denver
- St. Joseph Hospital - Denver
Arizona
- University of Arizona - Tucson
Florida
- University of Florida - Gainesville
Kentucky
- University of Kentucky - Lexington
Louisiana
- University Medical Center - New Orleans
Maine
- Maine Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 479 participants |
| Start Date | 2020-04-02 |
| Est. Completion | 2020-07-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04332991
The ClinicalTrials.gov registry entry for NCT04332991 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 479 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,381-participant average among 20 other Coronavirus trials with a reported enrollment target (65% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Coronavirus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04332991 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Massachusetts, Colorado.
Frequently Asked Questions
What is clinical trial NCT04332991 about?
NCT04332991 is a clinical study titled "Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease". ORCHID is a multicenter, blinded, placebo-controlled, randomized clinical trial evaluating hydroxychloroquine for the treatment of adults hospitalized with COVID-19. Patients, treating clinicians, and study personnel will all be blinded to study group assignment.
What is the current status of trial NCT04332991?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 479 participants. The study started on 2020-04-02. Estimated completion is 2020-07-23.
What conditions does trial NCT04332991 study?
This clinical trial studies the following conditions: Coronavirus, SARS-CoV Infection, Acute Respiratory Infection.
What interventions are being tested in trial NCT04332991?
The interventions under investigation include: Placebo (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT04332991?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04332991 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronavirus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
RECRUITING · Phase 3
-
Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses
RECRUITING
-
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
RECRUITING · NA
-
ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers
RECRUITING
-
A Study to Explore the Role of Gut Flora in COVID-19 Infection
RECRUITING
-
Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.